ストックスクリーナーアプリを入手
3.09
1.98%
0.06
前日終値:
$3.03
開ける：
$2.91
24時間の取引高:
7,393
Relative Volume:
0.15
時価総額：
$13.45M
収益：
$1.41M
当期純損益:
$-9.84M
株価収益率:
-1.4434
EPS:
-2.1408
ネットキャッシュフロー:
$-7.85M
1週間 パフォーマンス:
-5.94%
1か月 パフォーマンス:
-5.79%
6か月 パフォーマンス:
+5.82%
1年 パフォーマンス:
-36.68%
1日の値動き範囲:
$2.80
$3.09
1週間の範囲:
$2.75
$3.28
52週間の値動き範囲:
$2.15
$4.9149
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.09 | 13.45M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-05-18 | アップグレード | Maxim Group | Hold → Buy |
| 2017-02-13 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-08-17 | 繰り返されました | Maxim Group | Buy |
| 2015-07-27 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Bioline Rx Ltd Adr (BLRX) 最新ニュース
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
Enterprise value to revenue forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx reports preclinical data on GLIX1 with PARP inhibitor - Investing.com
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion - TipRanks
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
A41038 Forecast — Price Target — Prediction for 2027 - TradingView
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
BLRXBioline Rx Ltd ADR Stock Price and Quote - Finviz
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Morningstar
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Operating cash flow per share of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx launches trial of brain cancer drug GLIX1 By Investing.com - Investing.com South Africa
BioLineRx initiates Phase 1/2a study of GLIX1 - tipranks.com
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - investing.com
BioLineRx provides corporate update - tipranks.com
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips - Investing.com
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Finviz
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model - TipRanks
Bioline Rx Ltd Adr (BLRX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):